Clinical trial
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
NCT02954991 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
- Lead sponsor
- Mirati Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 7, 2016
- Completion date
- November 4, 2021
- Enrollment
- 161 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.